Drug Trial Radar · NCT01248195
Optimization of Treatment and Management of Schizophrenia in Europe
Last checked: Nov 19, 2026Latest source record: May 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
479
Actual
Start
May 2011
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- Rene KahnAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- King's College London; Technical University of Munich; University of Manchester; Ludwig-Maximilians - University of Munich
- First posted
- Nov 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, and will identify potential mechanisms for new drug development.
Conditions
- Schizophrenia
- Schizophreniform Disorder
- Schizoaffective Disorder
Interventions
Amisulpride open labelDrug
4-week open label amisulpride treatment
6-week amisulpride double blind treatmentDrug
6-week amisulpride double blind treatment
6-week olanzapine double blind treatmentDrug
6-week olanzapine double blind treatment
12-week clozapine open-label treatmentDrug
12-week clozapine open-label treatment
Psychosocial interventionBehavioral
Psychosocial intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- PANSSTime frame: Jan 2016
- Sellwood rating scaleTime frame: Jan 2016
- Biological profileTime frame: jan 2016
- MRS measuresTime frame: jan 2016
- SOFAS global functioningTime frame: jan 2016
- MRI assessmentsTime frame: jan 2016
Locations
26 sites in 16 countries. Site status is shown where the registry gives one.
Melbourne Neuropsychiatry Centre
Melbourne, Australia
Department of Biological Psychiatry, Innsbruck University Clinics
Innsbruck, Austria
Katholieke Universiteit Leuven (KU Leuven)
Leuven, Belgium
University Specialised Hospital for Active Treatment in Neurology and Psychiatry "St. Naum"
Sofia, Bulgaria
Psychiatrická klinika LF UK, Fakultní nemocnice
Hradec Králové, Czechia
Psychiatrické centrum Praha
Prague, Ustavni 91, Czechia
Center for Neuropsychiatric Research
Glostrup Municipality, Denmark
Institut National de la Santé et de la Reserche Médicale (INSERM)
Créteil, France
Martin-Luther-University (MLU) of Halle-Wittenberg
Halle, Germany
Deprtment of Psychiatry, University of Heidelberg
Mannheim, Germany
Ludwig-Maximilians University München
München, Germany
Technische Universität München (TUM)
München, Germany
Sheba Medical Centre Department of Psychiatry
Tel HaShomer, Israel
Department of Psychiatry University of Naples
Naples, Italy
University Medical Center Utrecht
Utrecht, Netherlands
Department of Adult Psychiatry, University of Medical Sciences
Poznan, Poland
Obregia Psychiatric Hospital
Bucharest, Romania
Hospital Clinic i Provincial
Barcelona, Spain
Servicio Madrileño de Salud (SERMAS)
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Instituto de Investigación Hospital 12 de Octubre
Madrid, Spain
Universidad de Oviedo
Oviedo, Spain
Clienia Schlössli AG, Privatklinik für Psychiatrie und Psychotherapie
Oetwil, Switzerland
King's College London, Departments of Psychological Medicine, Psychiatry & Cognitive Neuroscience
London, United Kingdom
West London Mental Health Trust
London, United Kingdom
University of Manchester
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.